**Testosterone production during puberty in two 46,XY patients with disorders of sex development and novel NR5A1 (SF-1) mutations**

Sally Tantawy, Lin Lin¹, Ilker Akkurt², Guntram Borck³, Dietrich Klingmüller⁴, Berthold P Haufa⁵, Heiko Krude, Heike Biebermann, John C Achermann⁵ and Birgit Köhler

Department of Pediatric Endocrinology, University Children’s Hospital, Charité, Humboldt University, Augustenburger Platz 1, 13353 Berlin, Germany. ¹UCL Institute of Child Health, University College London, London, UK, ²Children’s Hospital Altona, Hamburg, Germany. ³Institute of Human Genetics, University of Ulm, Ulm, Germany, ⁴Institute for Clinical Chemistry and Pharmacology, University of Bonn, Bonn, Germany and ⁵Department of Pediatric Endocrinology and Diabetes, University Children’s Hospital, University Duisburg-Essen, Essen, Germany

(Correspondence should be addressed to B Köhler; Email: birgit.koehler@charite.de)

**Abstract**

**Background:** Steroidogenic factor 1 (SF-1, NR5A1) is a key transcriptional regulator of many genes involved in the hypothalamic–pituitary–gonadal axis and mutations in NR5A1 can result in 46,XY disorders of sex development (DSD). Patients with this condition typically present with ambiguous genitalia, partial gonadal dysgenesis, and absent/rudimentary Müllerian structures. In these cases, testosterone is usually low in early infancy, indicating significantly impaired androgen synthesis. Further, Sertoli cell dysfunction is seen (low inhibin B, anti-Müllerian hormone). However, gonadal function at puberty in patients with NR5A1 mutations is unknown.

**Subjects and methods:** Clinical assessment, endocrine evaluation, and genetic analysis were performed in one female and one male with 46,XY DSD who showed spontaneous virilization during puberty. The female patient presented at adolescence with clitoral hypertrophy, whereas the male patient presented at birth with severe hypospadias and entered puberty spontaneously. Molecular analysis of NR5A1 was performed followed by *in vitro* functional analysis of the two novel mutations detected.

**Results:** Testosterone levels were normal during puberty in both patients. Analysis of NR5A1 revealed two novel heterozygous missense mutations in the ligand-binding domain of SF-1 (patient 1: p.L376F; patient 2: p.G328V). The mutant proteins showed reduced transactivation of the CYP11A promoter *in vitro*.

**Conclusion:** Patients with 46,XY DSD and NR5A1 mutations can produce sufficient testosterone for spontaneous virilization during puberty. Phenotypic females (46,XY) with NR5A1 mutations can present with clitoromegaly at puberty, a phenotype similar to other partial defects of androgen synthesis or action. Testosterone production in 46,XY males with NR5A1 mutations can be sufficient for virilization at puberty. As progressive gonadal dysgenesis is likely, gonadal function should be monitored in adolescence and adulthood, and early sperm cryopreservation considered in male patients if possible.

European Journal of Endocrinology 167 125–130

**Introduction**

Steroidogenic factor 1 (SF-1, NR5A1), a member of the nuclear receptor superfamily, is a key transcriptional regulator of many genes involved in the hypothalamic–pituitary–gonadal and hypothalamic–pituitary–adrenal axes (e.g. inhibin α, DAX1 (NR0B1), STAR (STAR), CYP11A (CYP11A1), CYP17A1, HSD3B2, CYP19A1, MIS (AMH), oxytocin, and SOX9) (1). SF-1 is highly expressed in steroidogenic tissues from very early stages of development, including the developing gonad and adrenal, and continues to be expressed in these tissues into adult life (2). SF-1 is also expressed in the ventromedial hypothalamic nucleus and pituitary gonadotropes (3, 4, 5). Consistent with this central role in reproductive and adrenal development, XY Sf-1 knockout mice (Sf-1<sup>−/−</sup>) lack adrenal glands and show male to female ‘sex reversal’ due to complete gonadal dysgenesis (6). Furthermore, male gonad-specific Sf-1<sup>−/−</sup> mice display hypoplastic testes and internal genitalia, undescended testes, and infertility (7). SF-1 interacts *in vitro* with several other major factors playing a role in gonadal determination and differentiation (e.g. SRY, GATA4, and SOX9) (8, 9, 10).

To date, about 50 different NR5A1 mutations have been reported in humans with disorders of sex development (DSD). NR5A1 mutations were first described in two 46,XY patients with complete gonadal dysgenesis and primary adrenal failure (11, 12) and in one 46,XX female with primary adrenal failure (13).
More recently, however, many more heterozygous NR5A1 mutations have been identified in patients with 46,XY DSD without adrenal insufficiency. The majority of these 46,XY DSD patients without adrenal failure have a phenotype of ambiguous genitalia at birth, partial gonadal dysgenesis, and absent or rudimentary Müllerian structures (14, 15, 16). The frequency of NR5A1 mutations in patients with this phenotype has been estimated to be about 15% (17, 18). Furthermore, NR5A1 mutations have also been identified in 46,XY patients with hypospadias and cryptorchidism, which is likely to be caused by a milder form of partial gonadal dysgenesis (19, 20), as well as in association with vanishing testis syndrome, micropenis, or infertility (21, 22, 23). In addition, SF-1 plays a role in ovarian development and function and mutations have been reported in women (46,XX) with primary ovarian insufficiency and premature ovarian failure (24). NR5A1 mutations rarely cause isolated adrenal insufficiency (25). Therefore, it is currently thought that disruption of SF-1 has a more significant effect on human gonadal development and function compared with human adrenal development and function (25).

In most published cases of 46,XY DSD due to NR5A1 mutations, testosterone has been low indicating significantly impaired androgen synthesis. Sertoli cell hypofunction has been suggested because of low levels of inhibin B and anti-Müllerian hormone (AMH) and elevated FSH. However, normal testosterone levels at birth have been reported in one patient with 46,XY DSD and low normal testosterone levels during puberty have been described in another patient (23, 26). We report two novel NR5A1 mutations in two patients with 46,XY DSD who demonstrate normal male testosterone production during puberty.

Subjects

Written informed consent for genetic analysis was obtained according to institutional ethical guidelines from the parents of patient 1 and from patient 2.

Patient 1

Patient 1 is a female who presented at puberty with clitoral hypertrophy. She was born to nonconsanguineous German Caucasian parents. The clinical presentation, endocrine and laparoscopic findings, and gonadal histology are summarized in Table 1. Psychological evaluation of the patient showed female gender identity. At 14 6/12 years, bilateral gonadectomy was performed with the patient’s consent and estrogen substitution was initiated. Mutations of 5α-reductase type 2 (SRD5A2), 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3), and androgen receptor (AR) genes were excluded. Basal cortisol was normal at puberty.

Patient 2

Patient 2 is a 28-year-old male who first presented at birth with severe penoscrotal hypospadias, hypoplastic phallus, and small inguinal testes. He was born to nonconsanguineous German Caucasian parents. In early infancy, a two-step surgical correction of hypospadias was carried out. The clinical presentation, testicular histology, results of laparoscopy, pubertal development, hormones, and semen analysis of the patient are summarized in Table 1. Mutations of the SRD5A2, AR, and LH/choriogonadotropin receptor (LHCGR) genes were excluded. Testosterone substitution was started at 28 years of age. Basal and stimulated cortisol (Synacthen test) levels were normal in adulthood.

Methods

Molecular analysis of NR5A1 gene

Molecular analysis of exons 2–7 of the gene encoding SF-1 (NR5A1) was performed as described previously (18). DNA mutation numbering is based on GenBank reference DNA sequence NM_004959.4, with the A of the ATG initiation codon designated +1 (www.hgvs.org/mutnomen).

Functional characterization

In vitro functional activities of the NR5A1 mutations on the murine Cyp11a promoter was assessed by transient gene expression assays in human embryonic kidney TSA-201 cells as described previously (17).

Results

Molecular genetic analysis and functional characterization

Analysis of the NR5A1 gene revealed a novel heterozygous missense mutation c.1126C>T (p.L376F, g.127253372) in exon 6 in patient 1 and a novel heterozygous missense mutation c.983G>T (p.G328V, g.127255316) in exon 5 in patient 2. Both mutations are located in the ligand-binding domain of SF-1 (Fig. 1). The p.L376F alteration is a de novo mutation as neither parents of patient 1 harbored this change. Only the mother of patient 2 was available for genetic analysis and she did not harbor the mutation. The mutated amino acids, leucine at position 376 and glycine at position 328, are highly conserved in SF-1 orthologs (Fig. 1). The c.1126C>T and c.983G>T variants are unlikely to be neutral nonpathological polymorphisms as they are not present in the database of single-nucleotide variants (dbSNP132) or the 1000 Genomes data (www.1000genomes.org/data).
Functional analysis of the mutants showed reduced activities to 12% (p.L376F) and 8% (p.G328V) of wild-type activity on the Cyp11a promoter (Fig. 2). No functional activity of the mutants on the AMH, TESCO, and INSL3 promoter was investigated as the two patients did not show either persistent uterine development as a sign of disturbed AMH secretion or severe gonadal dysgenesis as a result of impaired testes determination.

**Discussion**

We report two novel NR5A1 mutations (p.G328V and p.L376F) in two 46,XY DSD patients with normal male testosterone production at puberty. To date, knowledge about gonadal function at puberty in patients with 46,XY DSD and NR5A1 defects is very scarce, as most cases identified have undergone gonadectomy in early infancy. Only one 46,XY DSD patient with low normal testosterone production during puberty has been reported (26).

The first patient we describe (patient 1) is a 46,XY female who presented at puberty with clitoral hypertrophy, bilateral dysgenetic abdominal testes, no Müllerian structures, and inhibin B: <10 pg/ml. Laparoscopy: abdominal testes, no Müllerian structures. Testicular histology: bilateral testicular tissue, no spermatogenesis. Inhibin B: undetectable. Spermiogram: azoospermia.

The second patient (patient 2) presented at birth with severe penoscrotal hypospadias, small inguinal testes, penile length 2.5 cm, and normal testosterone levels. Laparoscopy: vaginal rest. Testicular histology: reduction of spermatogonia, increased intertubular tissue, thickening of the tunica albuginea. Inhibin B: undetectable. Spermiogram: azoospermia.

**Table 1** Clinical presentation, endocrine data, and other investigations of patients. Conversion to SI units: testosterone ng/ml × 3.47 for nmol/l; inhibin B pg/ml × 1.0 for pmol/l. Normal values for testosterone in males with Tanner stages 2–3, 0.62–2.26 ng/ml; Tanner stages 4–5, 1.68–6.0 ng/ml; normal testosterone peak after stimulation with HCG 5000 IU/m² at 0 h 0.20–4.0 ng/ml and at 72 h 3.0–10.0 ng/ml; basal FSH in males with Tanner stage 1, <1–1.3 IU/l; Tanner stages 2–3, <1–4.0 IU/l; Tanner stages 4–5, 1.4–5.1 IU/l; basal LH in males with Tanner stage 1, <1–1.5 IU/l; Tanner stages 2–3, 1–4.1 IU/l; Tanner stages 4–5, 3.4–7.5 IU/l; inhibin B, 74–470 pg/ml.

| Age (years) | Clinical presentation | Testosterone (ng/ml) | FSH (IU/l) | LH (IU/l) | Other investigations |
|------------|-----------------------|----------------------|------------|-----------|---------------------|
| Patient 1  | 14                    | B1, P4, A1 Clitoromegaly | 2.1            | 35.9      | 2.3                 | Karyotype: 46,XY Laparoscopy: abdominal testes, no Müllerian structures Testicular histology: bilateral testicular tissue, no spermatogenesis Inhibin B: <10 pg/ml Steroid profile: normal |
| Patient 2  | At birth | Severe penoscrotal hypospadias Small inguinal testes Penile length 1 cm Penile length 2.5 cm | NA            | NA        | NA                 | Karyotype: 46,XY |
|           | 3.5       |                                      | NA            | 0.6       | 0.9                | Laparoscopy: vaginal rest Testicular histology: reduction of spermatogonia, increased intertubular tissue, thickening of the tunica albuginea |
|           | 13.5      | G2, P2, A1 Gynecomastia B2 (3 cm <) Penile length 4.7 cm Right testis 5 ml, left testis 4 ml | 3.9 → 6.5 (after HCG 5000 IU/m²) | 25.9      | 3.4                | – |
|           | 16        | G4, P5, A3 Gynecomastia B4–5 (9 cm <) Penile length 7.1 cm Right testis 13 ml, left testis 15 ml | 2.6          | 35.4      | 7.0                | – |
|           | 19        | Penile length 6 cm Right testis 6 ml, left testis 6 ml | 3.3          | 37.9      | 10.9               | Surgery for gynecomastia |
|           | 28        | Right testis 6 ml, left testis 6 ml | 2.6          | 58.7      | 14.0               | Inhibin B: undetectable Spermiogram: azoospermia |

NA, not available; HCG, human chorionic gonadotrophin.
duct regression in patient 1. In patient 2, partially adequate AMH production and subsequent Müllerian/sexual Sertoli cell function was sufficient for embryonic and fetal development. In contrast, embryonic Leydig cell function had already been disturbed during gestation, as indicated by the low inhibin B concentrations, reflecting Leydig and Sertoli cell function change in SF-1/NR5A1 knockout mice. He entered puberty at the age of 28 years, but is unlikely to have been causative. Previously, we reported NR5A1 mutations in about 10% of patients with a similar phenotype of complex hypospadias at birth (severe hypospadias and/or hypoplastic phallus and cryptorchidism) (19, 20). However, only one patient with complex hypospadias at birth and uneventful testosterone production during puberty has been reported: Philibert et al. (26) described a 46,XY boy with hypospadias and micropenis at birth who was found to harbor a heterozygous NR5A1 mutation (p.R281P) in the ligand-binding domain of the protein. He entered puberty spontaneously with a low-normal rise of testosterone but had elevated FSH and decreased inhibin B concentrations, reflecting Leydig and Sertoli cell hypofunction.

Both patients reported in our study showed various degrees of underandrogenization at birth revealing that Leydig cell function had already been disturbed during embryonic and fetal development. In contrast, embryonic/fetal Sertoli cell function was sufficient for adequate AMH production and subsequent Müllerian duct regression in patient 1. In patient 2, partially impaired AMH production is suggested by the presence of a small Müllerian rest. Neither of the patients described showed any signs or symptoms of adrenal insufficiency as is the case with the majority of patients with heterozygous NR5A1 mutations published previously. Although detailed tests of adrenal function are not available for patient 1, we would currently recommend more comprehensive adrenal testing (e.g., cortisol response to Synacthen, and basal ACTH) and an ongoing awareness of the potential risk of adrenal failure in these patients. Further studies are required to systematically address the risk of adrenal dysfunction in such individuals in the long term.

In a recent study on male infertility, NR5A1 mutations were described in seven out of 199 (3.5%) males with moderate/severe oligospermia or azoospermia (23). All mutations were missense mutations in the hinge region or proximal ligand-binding domain of the protein. Notably, normal testosterone and low-normal/undetectable inhibin B levels were found in two patients under 30 years of age while the older patients had low to undetectable testosterone and inhibin B levels. These observations suggest that infertile males with NR5A1 mutations are at risk of deterioration of gonadal function with age (23).

Our study and the studies of Philibert et al. and Bashamboo et al. show that patients with NR5A1 mutations can produce significant levels of testosterone in adolescence and can enter puberty spontaneously. However, progressive gonadal dysgenesis resulting in oligospermia or azoospermia is potentially likely in individuals where spermatogenesis has occurred. Therefore, we strongly recommend regular monitoring of gonadal function in adolescence and adulthood in
males with NR5A1 mutations. If sperms are detected, early cryopreservation could be undertaken with appropriate genetic counseling in an attempt to preserve future chances of fertility.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This work was supported by the DAAD German Egyptian Long-term Scholarship (S Tantawy A1092239) and the Wellcome Trust Senior Fellowship (J C Achermann 079666).

**References**

1. Hoivik EA, Lewis AE, Aumo L & Bakke M. Molecular aspects of steroidogenic factor 1 (SF-1). *Molecular and Cellular Endocrinology* 2010 315 27–39. (doi:10.1016/j.mce.2009.07.003)

2. Parker KL, Rice DA, Lala DS, Ikeda Y, Luo X, Wong M, Bakke M, Zhao L, Frigeri C, Hanley NA, Stallings N & Schimmer BP. Steroidogenic factor 1: an essential mediator of endocrine development. *Recent Progress in Hormone Research* 2002 57 19–36. (doi:10.1210/rp.57.1.19)

3. Ikeda Y, Shen WH, Ingraham HA & Parker KL. Developmental expression of mouse steroidogenic factor-1, an essential regulator of the steroid hydroxylases. *Molecular Endocrinology* 1994 8 654–662. (doi:10.1210/me.8.5.654)

4. Shinoda K, Lei H, Yoshii H, Nomura M, Nagano M, Shiba H, Sasaki H, Osawa Y, Ninomiya Y, Niwa O, Morohashi K-I & Li E. Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice. *Developmental Biology* 1995 204 22–29. (doi:10.1002/aja.1002040104)

5. Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen WH, Nachtigal MW, Abbud R, Nilson JH & Parker KL. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. *Genes and Development* 1994 8 2302–2312. (doi:10.1101/gad.8.19.2302)

6. Luo X, Ikeda Y & Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. *Cell* 1994 77 481–490. (doi:10.1016/0092-8674(94)90211-9)

7. Jeyasuria P, Ikeda Y, Jamin SP, Zhao L, De Roeulx DG, Thermen AP, Behringer RR & Parker KL. Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in gonadal function. *Molecular Endocrinology* 2004 18 1610–1619. (doi:10.1210/me.2003-0040)

8. Shen WH, Moore CC, Ikeda Y, Parker KL & Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates the Mullerian inhibiting substance gene: a link to the sex determination cascade. *Cell* 1994 77 651–661. (doi:10.1016/0092-8674(94)90050-7)

9. Giuli G, Shen WH & Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian inhibiting substance, in vivo. *Development* 1997 124 1799–1807.

10. De Santa Barbara P, Bonneau N, Boizet B, Desclouzeaux M, Moniot B, Sudbeck P, Scherer G, Poulat F & Berta P. Direct interaction of SRV-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Mullerian hormone gene. *Molecular and Cellular Biology* 1998 18 6653–6665.

11. Achermann JC, Ito M, Ito M, Hindmarsh PC & Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. *Nature Genetics* 1999 22 125–126. (doi:10.1038/36296)

12. Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B & Jameson JL. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor 1, in a dose-dependent manner. *Journal of Clinical Endocrinology and Metabolism* 2002 87 1829–1833. (doi:10.1210/jc.87.4.1829)

13. Biaison-Lauer B & Schoenle EJ. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. *American Journal of Human Genetics* 2000 67 1563–1568. (doi:10.1086/316893)

14. Domenice S, Correia RV, Costa EM, Nishi MY, Vilain E, Arnhold HJ & Mendonca BB. Mutations in the SRY, DAX1, SF1 and WNT4 genes in Brazilian sex-reversed patients. *Brazilian Journal of Medical and Biological Research* 2004 37 145–150. (doi:10.1590/S0100-879X2004000100020)

15. Mallet D, Bretones P, Michel-Calemard L, Djoud F, David M & Morel Y. Gonadal dysgenesis without adrenal insufficiency in a 46,XY patient heterozygous for the nonsense C16X mutation: a case of SF1 haploinsufficiency. *Journal of Clinical Endocrinology and Metabolism* 2004 89 4829–4832. (doi:10.1210/jc.2004-0670)

16. Hasegawa T, Fukami M, Sato N, Katsumata N, Sasaki G, Fukutani K, Morohashi K & Ogata T. Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactivating mutation of steroidogenic factor-1. *Molecular Endocrinology* 2004 89 5930–5935. (doi:10.1210/jc.2004-0935)

17. Lin L, Philibert P, Ferraz-de-Souza B, Kelberman D, Homfray T, Albanese A, Molini V, Sebire NJ, Einaudi S, Conway GS, Hughes IA, Jameson JL, Sultan C, Diattani MT & Achermann JC. Heterozygous nonsense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function. *Journal of Clinical Endocrinology and Metabolism* 2007 92 991–999. (doi:10.1210/jc.2006-1672)

18. Kohler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schroder V, Biebemmer H, Schnabel D, Gruters A & Achermann JC. Five novel mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY sex development and normal adrenal function. *Journal of Clinical Endocrinology and Metabolism* 2007 92 651–659. (doi:10.1002/humu.20588)

19. Kohler B, Lin L, Mazen I, Cetindag C, Biebemmer H, Akkurt I, Rossi R, Hiort O, Gruters A & Achermann JC. The spectrum of phenotypes associated with mutations in steroidogenic factor 1 (SF1, NR5A1, Ad4BP) includes severe penoscrotal hypospadias in 46,XY males without adrenal insufficiency. European *Journal of Endocrinology* 2009 161 237–242. (doi:10.1530/EJE-09-0067)

20. Warman DM, Costanzo M, Marino R, Berenstein E, Galeano J, Ramirez PC, Saraco N, Baquedano MS, Ciaccio M, Guercio G, Chaler E, Maceiras M, Lazzatti JM, Bailez M, Rivarola MA & Berengosky A. Three new SF-1 (NR5A1) gene mutations in two unrelated families with multiple affected members: within-family variability in 46,XY subjects and low ovarian reserve in fertile 46,XX subjects. *Hormone Research inPediatrics* 2011 75 70–77. (doi:10.1159/000320029)

21. Philibert P, Zentaty D, Lin L, Soskin S, Audran F & Leger J, Achermann JC & Sultan C. Mutational analysis of steroidogenic factor 1 (SF-1, NR5A1, Ad4BP) in 24 boys with bilateral anorchia: a French collaborative study. *Humana Reproduction* 2007 22 3255–3261. (doi:10.1093/humrep/dei278)

22. Paris F, De Ferran K, Bhangoo A, Ten S, Lagerlof M, Aiona, M, Roca de Bofill C, Vassal B, Abarbanel A, Hantmann C, Campo R, Lahlou N, Audran F, Leger J, Behringer RR & Sultan C. Isolated ‘idiopathic’ micropenis: hidden genetic defects? *American Journal of Human Genetics* 2010 87 505–512. (doi:10.1016/j.ajhg.2010.09.009)
24 Lourenco D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, Boudjenah R, Guerra-Junior G, Maciel-Guerra AT, Achermann JC, McElreavey K & Bashamboo A. Mutations in NR5A1 associated with ovarian insufficiency. *New England Journal of Medicine* 2009 **360** 1200–1210. (doi:10.1056/NEJMoa0806228)

25 Lin L, Gu WX, Ozisik G, To WS, Owen CJ, Jameson JL & Achermann JC. Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years’ experience. *Journal of Clinical Endocrinology and Metabolism* 2006 **91** 3048–3054. (doi:10.1210/jc.2006-0603)

26 Philibert P, Polak M, Colmenares A, Lortat-Jacob S, Audran F, Poulat F & Sultan C. Predominant Sertoli cell deficiency in a 46,XY disorders of sex development patient with a new NR5A1/SF-1 mutation transmitted by his unaffected father. *Fertility and Sterility* 2011 **1788** e1785–e1789.

Received 2 November 2011
Revised version received 17 February 2012
Accepted 3 April 2012